98%
921
2 minutes
20
Immunosensors are promising analytical tools for screening and diagnosis of cervical cancer (CC) due to being practical, rapid and economical as compared with conventional methods. Choosing a sensible and specific tumor marker (TM) serving as target which is immobilized on sensor surface is a crucial step for a CC immunosensor. In addition, the transducer design involving optical, piezoelectric or electrochemical converting of antigen-antibody interaction in the analytical signals could be projected to achieve a maximal sensitivity, guarantying accuracy in the detection of CC. This review aims to describe more important TMs and transducers used for the development of immunosensors for CC. An overview of experimental articles published in the last decade designed to detect TM associated with CC, using optical, electrochemical and piezoelectric transductions mode are discussed. Although serological TM, such as SCCa, CEA and CA125 are still predominantly used, new biomarkers including the P16, MCM5 and PP1γ2 have been considered specific and reliable for CC diagnostic. Recently, new strategies such as multiplex assays and samples obtained directly from tumor tissue, as well self-sampling, have been proposed to overcome several limitations. Optical and electrochemical are the most popular transducers, and nanoparticles as electrochemical probes and sandwich assays have been the strategies for increasing the limit of detection and sensitivity of immunosensors for CC diagnostic.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/0115680266366335250314081522 | DOI Listing |
JCO Glob Oncol
May 2025
Department of Obstetrics and Gynaecology, Stanford University School of Medicine, Stanford, CA.
Purpose: Expanding high-risk human papillomavirus (HPV) vaccine coverage in resource-constrained settings is critical to bridging the cervical cancer gap and achieving the global action plan for elimination. Mobile health (mHealth) technology via short message services (SMS) has the potential to improve HPV vaccination uptake. The mHealth-HPVac study evaluated the effectiveness of mHealth interventions in increasing HPV vaccine uptake among mothers of unvaccinated girls aged 9-14 years in Lagos, Nigeria.
View Article and Find Full Text PDFMenopause
September 2025
Department of Gynecologic Oncology, Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY.
Objective: Endometrial cancer (EC) and epithelial ovarian cancer (EOC) affect women of all ages, and the incidence of endometrial cancer in premenopausal women is rising. Menopause can be detrimental to longevity and quality of life, but evidence suggests estrogen therapy (ET) is safe in these patients. The purpose of this study was to evaluate the practice patterns of gynecologists and gynecologic oncologists (GYO) in the United States in regards to prescription of ET to gynecologic cancer patients.
View Article and Find Full Text PDFPLOS Glob Public Health
September 2025
Department of Child, Family, and Population Health Nursing, School of Nursing, University of Washington, Seattle, Washington, United States of America.
Cervical cancer continues to be a major global threat to women's health, with approximately 660,000 women diagnosed annually, 94% of whom are in low- and middle-income countries (LMICs). The high disease burden in LMICs is partly due to suboptimal adoption and widespread implementation of effective preventive interventions. This study explored drivers of implementation success and failure for a future single-visit, screen, and treat approach with thermal ablation (SV-SAT + TA), referred to as TIBA in Kenya.
View Article and Find Full Text PDFAm J Case Rep
September 2025
Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan.
BACKGROUND This study reports on 2 cases of cervical melanoma with similar presentations but at different stages, and the treatment strategy varied accordingly, and we review the literature on the characteristics, diagnosis, and management of cervical melanoma. CASE REPORT Case 1: A 69-year-old woman with abnormal vaginal bleeding was diagnosed with advanced cervical melanoma, staged as International Federation of Gynecology and Obstetrics (FIGO) Stage IVB, involving multiple metastases. Despite chemoradiotherapy and immunotherapy (nivolumab), the disease progressed rapidly, and the patient died 4 months after diagnosis.
View Article and Find Full Text PDFObstet Gynecol
July 2025
Ana I. Tergas is from the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Health, Rutgers New Jersey Medical School, Newark, New Jersey. Mark H. Einstein is from the Department of Obstetrics, Gynecology, and Women's Health, Albert Einstein College of Medicine